Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01433965 · ClinicalTrials.gov registry record · Phase 1
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01433965 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 16 participants.
The verdict
NCT01433965, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-08-08 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01433965
The ClinicalTrials.gov registry entry for NCT01433965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01433965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01433965 about?
NCT01433965 is a clinical study titled "Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
What is the current status of trial NCT01433965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-08-08. Estimated completion is 2021-01-12.
What interventions are being tested in trial NCT01433965?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01433965?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.